Cuộc họp công bố kết quả kinh doanh Q2 2026 của ADC Therapeutics (ADCT): Mối quan ngại của FDA về LOTIS-5, 219,1 triệu USD tiền mặt
Cuộc họp báo cáo kết quả kinh doanh quý 2/2026 của ADC Therapeutics: Doanh thu ZYNLONTA đạt 18,6 triệu USD, trong khi những lo ngại từ FDA làm phủ bóng lên tiến trình phê duyệt pháp lý của LOTIS-5.
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.